Core Insights - Polyrizon Ltd. has concluded 2025 with a strong cash position of approximately $17.5 million and a debt-free balance sheet, enabling significant advancements in its innovative nasal programs [2][5] - The company has made key regulatory progress with the FDA, including a productive Pre-Submission Meeting for its allergy blocker NASARIX™ and submitted a Pre-Request for Designation for its viral blocker [5] - Polyrizon is exploring potential revenue-generating investment opportunities in high-growth sectors such as private aviation and advanced eVTOL drone technologies, while maintaining financial flexibility [2] Company Achievements - The branding process for the allergy blocker NASARIX™ has been completed [2] - Positive preclinical data has been reported across multiple programs, including enhanced nasal deposition and mucoadhesion for the intranasal Naloxone Hydrogel program [5] - The company has signed an agreement with a leading global Preclinical CRO to support its clinical development pathway, with studies expected to commence in Q2 2026 [5] Technology Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [3] - The proprietary Capture and Contain™ hydrogel technology functions as a "biological mask" and is being further developed for drug delivery [3] - An additional technology, Trap and Target™, is focused on the nasal delivery of active pharmaceutical ingredients and is in earlier stages of pre-clinical development [3]